ArticleHepatology (Baltimore, Md.)2017
Patient-reported barriers are associated with lower hepatocellular carcinoma surveillance rates in patients with cirrhosis.
Article in Hepatology (Baltimore, Md.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 107 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
107 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Synthesising enablers and barriers to hepatocellular carcinoma surveillance-A systematic review of qualitative findings.PloS one · 2025Pooled it
- Guideline
- Financial Burden of Hepatocellular Carcinoma Screening in Patients With Cirrhosis.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2024Trial
- A randomized trial of mailed outreach with behavioral economic interventions to improve liver cancer surveillance.Hepatology communications · 2024Trial
- Multicenter Randomized Clinical Trial of a Mailed Outreach Strategy for Hepatocellular Carcinoma Surveillance.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2022Trial
- Novel Application of Predictive Modeling: A Tailored Approach to Promoting HCC Surveillance in Patients With Cirrhosis.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2022Trial
- Mailed Outreach Invitations Significantly Improve HCC Surveillance Rates in Patients With Cirrhosis: A Randomized Clinical Trial.Hepatology (Baltimore, Md.) · 2019Trial
- Missed Diagnosis in Alcohol-Related Hepatocellular Carcinoma: A Call for Alcohol Consumption and Liver Disease Early Detection.Liver international : official journal of the International Association for the Study of the Liver · 2026Review
- Hepatocellular carcinoma surveillance in Europe: challenges and lessons from global practice.The Lancet regional health. Europe · 2026Review
- [Pathogenic mechanisms and advances in the diagnosis and treatment of co-occurring psychiatric and psychological symptoms in patients with liver cirrhosis].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Review
- Cost-effectiveness of HES V2.0 and GALAD for hepatocellular carcinoma surveillance in patients with cirrhosis.Hepatology communications · 2026Article
- Characterizing Social Determinants of Health in Patients With Type 2 Diabetes and Liver Disease: Cross-Sectional Survey Study.JMIR formative research · 2026Article
- Hepatocellular carcinoma surveillance: a health economic evaluation.Clinical and molecular hepatology · 2026Review
- Risk-stratified surveillance for hepatocellular carcinoma.Hepatology communications · 2026Review
- Disparities in Diagnosis, Management, and Outcomes of Hepatocellular Carcinoma: A Review of Global and Sociodemographic Factors.Journal of gastrointestinal cancer · 2026Review
- Social Determinants of Health Are Associated With Treatment Receipt and Mortality in Patients With Hepatocellular Carcinoma.Journal of the National Comprehensive Cancer Network : JNCCN · 2026Article
- Inequalities in hepatocellular carcinoma (HCC) surveillance uptake in London: a UK multicentre cohort study.BMJ public health · 2026Article
- Patient-, Provider-, and Area-Level Factors Associated with Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis in North Carolina.North Carolina medical journal · 2025Article
- Evaluating chat generative pretrained transformer in answering questions on endoscopic mucosal resection and endoscopic submucosal dissection.World journal of gastrointestinal oncology · 2025Article
- Article
47 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
10 authors.
Funding
Abstract
Over 20% of patients with cirrhosis are nonadherent with hepatocellular carcinoma (HCC) surveillance recommendations; however, few studies have evaluated the impact of patient-level factors on surveillance receipt. We characterized the association between HCC surveillance receipt and patient knowledge, attitudes, and perceived barriers in a racially diverse and socioeconomically disadvantaged cohort of patients with cirrhosis. Patients with cirrhosis followed at a large urban hospital were invited to complete a survey about HCC surveillance between August 2014 and December 2015. Multivariable logistic regression was performed to identify factors associated with HCC surveillance receipt during the 12-month period preceding and 6-month period after survey administration. We achieved a response rate of 71.8% (n = 541 of 753). Patients demonstrated high levels of HCC-related knowledge (summary score, 77.7%); however, 48.6% believed that eating a healthy diet precluded the need for HCC surveillance, and 34.0% believed that HCC surveillance was not necessary if they had a normal physical exam and/or lacked clinical symptoms. Patients expressed worry about developing and dying from HCC, but nearly half (49.9%) of patients reported barriers to receiving HCC surveillance, including difficulty with the scheduling process (30.5%), costs of surveillance testing (25.3%), and transportation difficulties (17.3%). HCC surveillance receipt was significantly higher in patients who knew cirrhosis is a risk factor for developing HCC (odds ratio [OR], 3.09; 95% confidence interval [CI], 1.25-7.62) and significantly lower in those reporting barriers to surveillance (OR, 0.42; 95% CI, 0.25-0.70).
conclusionPatients with cirrhosis are knowledgeable and interested in HCC surveillance; however, patient-reported barriers are associated with lower surveillance rates in clinical practice and represent potential intervention targets to improve HCC surveillance effectiveness. (Hepatology 2017;65:875-884).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.